Adiponectin and Vulnerable Atherosclerotic Plaques

Barseghian, Ailin; Gawande, Dipika; Bajaj, Mandeep S

doi:10.1016/j.jacc.2010.11.011

Cited by 70 publications

(43 citation statements)

References 135 publications

(150 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Pioglitazone increases adiponectin levels in a dose-dependent manner [21]. Adiponectin is known to exert antiatheroscelerotic actions such as antithrombotic and anti-inflammatory effects [22]. Decreased adiponectin levels, which are often observed in subjects with T2DM as compared to non-diabetic subjects [23], are associated with an increased CHD risk [23].…”

Section: Discussionmentioning

confidence: 99%

Pioglitazone treatment and cardiovascular event and death in subjects with type 2 diabetes without established cardiovascular disease (JDDM 36)

Yokoyama

Araki

Kawai

et al. 2015

Diabetes Research and Clinical Practice

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Pioglitazone treatment and cardiovascular event and death in subjects with type 2 diabetes without established cardiovascular disease (JDDM 36)

Yokoyama

Araki

Kawai

et al. 2015

Diabetes Research and Clinical Practice

View full text Add to dashboard Cite

“…Patients received 350 mg/day (in the GE-resveratrol, 8 mg resveratrol) for the first six months of the study and 700 mg/day (16 mg resveratrol) for the next 6 months. The patients receiving GE-resveratrol had increased levels of the anti-inflammatory adipokine, adiponectin, and a reduction in the thrombogenic plasminogen activator inhibitor type 1 (PAI-1), suggesting that resveratrol may be cardioprotective, since increasing adiponectin [197] and/or decreasing PAI-1 [198] has been proposed to be a promising therapy for CAD. Moreover, there was a down regulation of pro-inflammatory genes expressed in peripheral blood mononuclear cells (PBMCs) in the GE-resveratrol group.…”

Section: Clinical Studiesmentioning

confidence: 99%

Preclinical and clinical evidence for the role of resveratrol in the treatment of cardiovascular diseases

Zordoky

Robertson

Dyck

2015

Biochimica et Biophysica Acta (BBA) - Molecular Basis of Diseas

275

217

View full text Add to dashboard Cite

Cardiovascular disease is the leading cause of death worldwide. Despite advancements in diagnosis and treatment of cardiovascular disease, the incidence of cardiovascular disease is still rising. Therefore, new lines of medications are needed to treat the growing population of patients with cardiovascular disease. Although the majority of the existing pharmacotherapies for cardiovascular disease are synthesized molecules, natural compounds, such as resveratrol, are also being tested. Resveratrol is a non-flavonoid polyphenolic compound, which has several biological effects. Preclinical studies have provided convincing evidence that resveratrol has beneficial effects in animal models of hypertension, atherosclerosis, stroke, ischemic heart disease, arrhythmia, chemotherapy-induced cardiotoxicity, diabetic cardiomyopathy, and heart failure. Although not fully delineated, some of the beneficial cardiovascular effects of resveratrol are mediated through activation of silent information regulator 1 (SIRT1), AMP-activated protein kinase (AMPK), and endogenous anti-oxidant enzymes. In addition to these pathways, the anti-inflammatory, anti-platelet, insulin-sensitizing, and lipid-lowering properties of resveratrol contribute to its beneficial cardiovascular effects. Despite the promise of resveratrol as a treatment for numerous cardiovascular diseases, the clinical studies for resveratrol are still limited. In addition, several conflicting results from trials have been reported, which demonstrates the challenges that face the translation of the exciting preclinical findings to humans. Herein, we will review much of the preclinical and clinical evidence for the role of resveratrol in the treatment of cardiovascular disease and provide information about the physiological and molecular signaling mechanisms involved. This article is part of a Special Issue entitled: Resveratrol: Challenges in translating pre-clinical findings to improved patient outcomes.

show abstract

“…These alterations affect the function of adipose tissue [13][14][15][16] and induce changes in the microenvironment that contribute to the recruitment of inflammatory cell leading to a state of chronic low grade inflammation [17,18].…”

Section: Obesity and Inflammationmentioning

confidence: 99%

Adipokines and their Involvement as a Target of New Drugs

Raimo¹

2015

J Pharmacovigil

View full text Add to dashboard Cite

Globesity is referred to a global epidemic of obesity, affecting millions of individuals. Molecules released by the enlarged adipose tissue, most of which are pro-inflammatory, have been named adipokines. The present review deals with function, molecular targets and the potential clinical relevance of adipokines. Currently, more than 600 adipokines have been identified, many of them, including leptin, visfatin, resistin as well as Retinol Binding Protein4 may serve as informative markers for metabolic and cardiovascular diseases and play important roles in glucose homeostasis, insulin sensitivity as well as metabolic regulation of energy expenditure. Adiponectin on the contrary exerts anti-inflammatory and insulin sensitizing activity. Adiponectin has additional anti-atherogenic effects and low adiponectin serum concentrations are associated with in creased risk for cardiovascular diseases. The understanding of the role of adipokines has provided a wealth of information that has opened great opportunities for new therapeutic advances. Adiponectin may be the most prominent example for the potential use of an adipokine in the treatment of obesity and obesity-associated metabolic diseases. In many studies, administration of recombinant adiponectin results in improved insulin sensitivity, increased insulin secretion and beneficial effects on body weight and hyperglycemia. Up-regulation of adiponectin/adiponectin receptors or enhancing adiponectin receptor function may be an interesting therapeutic strategy for obesity-linked insulin resistance. Moreover, the therapeutic use of combined amylin/leptin agonism (with pramlintide and metreleptin) demonstrated a significant weight-lowering effect in obese subjects. Therefore, adipokines may be clinically relevant either as therapeutic tools or as target in the treatment of obesity related diseases. Journal of PharmacovigilanceJou rn a l o f P harma c o v ig il a nc e

show abstract

Adiponectin and Vulnerable Atherosclerotic Plaques

Cited by 70 publications

References 135 publications

Pioglitazone treatment and cardiovascular event and death in subjects with type 2 diabetes without established cardiovascular disease (JDDM 36)

Pioglitazone treatment and cardiovascular event and death in subjects with type 2 diabetes without established cardiovascular disease (JDDM 36)

Preclinical and clinical evidence for the role of resveratrol in the treatment of cardiovascular diseases

Adipokines and their Involvement as a Target of New Drugs

Contact Info

Product

Resources

About